Associate Professor Lisa Ebert (B.Sc. (Hons), PhD) is a clinically-oriented cancer research scientist, with a particular interest in immunology and cancer immunotherapy.
She completed her PhD at the University of Adelaide, before undertaking post-doctoral research at the University of Bern (Switzerland) and the Ludwig Institute for Cancer Research (Melbourne). During this time, she developed particular expertise in human immunology, cancer cell biology, multi-parameter flow cytometry and immune monitoring of cancer immunotherapy clinical trials.
Now, A/Prof Ebert is a Group Leader of Cancer Immunotherapy Research, within the Translational Oncology Laboratory at the Centre for Cancer Biology (CCB) - an alliance... Read more
About me
Associate Professor Lisa Ebert (B.Sc. (Hons), PhD) is a clinically-oriented cancer research scientist, with a particular interest in immunology and cancer immunotherapy.
She completed her PhD at the University of Adelaide, before undertaking post-doctoral research at the University of Bern (Switzerland) and the Ludwig Institute for Cancer Research (Melbourne). During this time, she developed particular expertise in human immunology, cancer cell biology, multi-parameter flow cytometry and immune monitoring of cancer immunotherapy clinical trials.
Now, A/Prof Ebert is a Group Leader of Cancer Immunotherapy Research, within the Translational Oncology Laboratory at the Centre for Cancer Biology (CCB) - an alliance between UniSA and SA Pathology. Her research is aimed at understanding interactions between cancer cells and the immune system, and using this knowledge to improve cancer treatment. Key focus areas include developing new immunotherapy approaches for treating glioblastoma (brain tumours) and optimising the therapeutic efficacy of checkpoint inhibitors in melanoma. For further details on A/Prof Ebert's current research, refer to the CCB website: https://www.centreforcancerbiology.org.au/research/translational-oncology-laboratory/
A/Prof Ebert has co-authored numerous papers in the fields of immunology and cancer - click on the green ORCID ID badge to the right for details. She currently holds research grants from the NHMRC, Cancer Australia, Ray & Shirl Norman Cancer Research Trust, the Neurosurgical Research Foundation and others, and supervises several Honours, Masters and PhD students. Enquiries from prospective students are welcome.
Research
Excludes commercial-in-confidence projects.
Defining the therapeutic potential of eosinophils in melanoma, Australian Melanoma Research Foundation, 01/02/2025 - 31/01/2026
Exploiting blood vessels as conduits for the entry of therapeutic CAR-T cells into brain tumours, Neurosurgical Research Foundation, 02/10/2023 - 31/10/2025
Desmoglein-2; an unsuspected regulator of melanoma, NHMRC - Project Grant, 01/01/2019 - 31/12/2022
Development of a new therapy for glioblastoma based on chimeric antigen receptor (CAR)-T cells, Tour de Cure Ltd, 01/01/2021 - 31/12/2022
Checkpoint blockade immunotherapy in melanoma: getting tumour-killing T cells to their site of action, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Validation of a novel therapeutic target in multiple myeloma, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2024 |
Open access
|
| 2024 |
Open access
17
|
| 2024 |
Open access
3
4
|
| 2024 |
Open access
5
6
1
|
| 2024 |
Open access
3
2
4
|
| 2023 |
Open access
6
6
|
| 2023 |
Open access
10
9
|
| 2023 |
Open access
1
|
| 2023 |
Open access
4
5
2
|
| 2023 |
Open access
7
8
|
| 2023 |
Open access
8
6
4
|
| 2023 |
Open access
7
5
|
| 2022 |
Open access
11
12
13
|
| 2022 |
Open access
64
61
|
| 2022 |
Open access
21
18
|
| 2022 |
Open access
16
17
4
|
| 2021 |
Open access
33
32
5
|
| 2021 |
Open access
13
|
| 2021 |
Open access
23
21
4
|
| 2021 |
Open access
30
26
|
| 2021 |
Open access
51
48
|
| 2020 |
Open access
51
46
4
|
| 2020 |
Open access
24
20
3
|
| 2020 |
Open access
44
38
8
|
| 2019 |
Open access
37
35
|
| 2019 |
29
30
|
| 2019 |
Open access
9
9
|
| 2019 |
121
114
9
|
| 2018 |
25
24
|
| 2017 |
13
13
|
| 2017 |
Open access
26
26
3
|
| 2016 |
Open access
34
35
|
| 2016 |
Open access
43
43
1
|
| 2015 |
Open access
16
15
4
|
| 2015 |
Open access
64
61
|
| 2013 |
5
5
|
| 2012 |
5
4
|
| 2012 |
Open access
52
53
|
External engagement & recognition
| Organisation | Country |
|---|---|
| Austin Health | AUSTRALIA |
| CSL Limited | AUSTRALIA |
| Ferronova | AUSTRALIA |
| Flinders Medical Centre | AUSTRALIA |
| Flinders University | AUSTRALIA |
| H. Lee Moffitt Cancer Center | UNITED STATES |
| Harvard University | UNITED STATES |
| Hebrew University | MEXICO |
| InterVenn Biosciences | UNITED STATES |
| La Trobe University | AUSTRALIA |
| Ludwig Institute for Cancer Research | AUSTRALIA |
| Mashhad University of Medical Sciences | IRAN |
| Miltenyi Biotec | GERMANY |
| Peter MacCallum Cancer Centre | AUSTRALIA |
| Purdue University | UNITED STATES |
| Queensland University of Technology | AUSTRALIA |
| Royal Adelaide Hospital | AUSTRALIA |
| Royal Melbourne Hospital | AUSTRALIA |
| SA Pathology | AUSTRALIA |
| South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
| Telethon Kids Institute | AUSTRALIA |
| Thomas Jefferson University | UNITED STATES |
| University of Adelaide | AUSTRALIA |
| University of California | UNITED STATES |
| University of New South Wales | AUSTRALIA |
| University of Pittsburgh Medical Center | UNITED STATES |
| University of Queensland | AUSTRALIA |
| University of South Australia | AUSTRALIA |
| University of Sydney | AUSTRALIA |
| University of Western Australia | AUSTRALIA |
| Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
| Western Sydney University | AUSTRALIA |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| 110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy | Current |
| Enhancing cancer immunotherapy success by efficient recruitment of T cells to solid tumours | Current |
| Identifying optimal immunotherapy combinations for the treatment of brain tumours | Current |
| Targeting cancer cell invasion for new personalised therapeutic approaches against glioblastoma | Current |
| Tumour protein D54 as a regulator of melanoma progression | Current |
| Optimising CAR T cell manufacturing for solid cancers | Completed |
| Preclinical development of GD2 CAR-T cell therapy for glioblastoma | Completed |
| The role of platelets in vasculogenic mimicry | Completed |
| Vasculogenic mimicry: regulation and function in melanoma | Completed |
